Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125914 | 0.89 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL5125907 | 0.89 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL3963573 | 0.89 | GFER (0.43) | ALDH1A1L3MBTL1KCNK3KCNK9GFER | |
| SCHEMBL5129442 | 0.88 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL5129445 | 0.88 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL5128594 | 0.88 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL5128596 | 0.88 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL5125842 | 0.87 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL5125838 | 0.87 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 | |
| SCHEMBL3955479 | 0.87 | KCNK3 (0.42) | ALDH1A1L3MBTL1NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | claimed |
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | SCN1A, SCN3A, SCN1B | ALDH1A1 1009/4885L3MBTL1 2597/4885NPC1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.